JP6009457B2 - ポリマー−デスエチルスニチニブコンジュゲート - Google Patents

ポリマー−デスエチルスニチニブコンジュゲート Download PDF

Info

Publication number
JP6009457B2
JP6009457B2 JP2013546457A JP2013546457A JP6009457B2 JP 6009457 B2 JP6009457 B2 JP 6009457B2 JP 2013546457 A JP2013546457 A JP 2013546457A JP 2013546457 A JP2013546457 A JP 2013546457A JP 6009457 B2 JP6009457 B2 JP 6009457B2
Authority
JP
Japan
Prior art keywords
ethyl
compound
polymer
carboxamido
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013546457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501765A5 (enExample
JP2014501765A (ja
Inventor
アントニ コズロウスキ,
アントニ コズロウスキ,
ショーン エム. カルバートソン,
ショーン エム. カルバートソン,
シャオミン シェン,
シャオミン シェン,
サミュエル ピー. マクマナス,
サミュエル ピー. マクマナス,
マーク エー. ウィルソン,
マーク エー. ウィルソン,
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2014501765A publication Critical patent/JP2014501765A/ja
Publication of JP2014501765A5 publication Critical patent/JP2014501765A5/ja
Application granted granted Critical
Publication of JP6009457B2 publication Critical patent/JP6009457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyethers (AREA)
JP2013546457A 2010-12-23 2011-12-23 ポリマー−デスエチルスニチニブコンジュゲート Active JP6009457B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426893P 2010-12-23 2010-12-23
US61/426,893 2010-12-23
PCT/US2011/067240 WO2012088522A1 (en) 2010-12-23 2011-12-23 Polymer-des-ethyl sunitinib conjugates

Publications (3)

Publication Number Publication Date
JP2014501765A JP2014501765A (ja) 2014-01-23
JP2014501765A5 JP2014501765A5 (enExample) 2014-12-25
JP6009457B2 true JP6009457B2 (ja) 2016-10-19

Family

ID=45496320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546457A Active JP6009457B2 (ja) 2010-12-23 2011-12-23 ポリマー−デスエチルスニチニブコンジュゲート

Country Status (4)

Country Link
US (2) US10220020B2 (enExample)
EP (1) EP2654797B1 (enExample)
JP (1) JP6009457B2 (enExample)
WO (1) WO2012088522A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088506A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-semaxanib moiety conjugates
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
US10220020B2 (en) * 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
EP3228650B1 (en) * 2014-12-04 2022-03-09 Delta-Fly Pharma, Inc. Novel peg derivative
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
CN111995513B (zh) * 2019-05-27 2022-11-01 天津键凯科技有限公司 一种9-羟甲基-芴二酸的制备方法
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
WO2022103983A2 (en) * 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2395461C (en) 1999-12-22 2010-05-25 Sugen, Inc. Methods of modulating c-kit tyrosine kinase function with indolinone compounds
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
WO2001083450A2 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US7053144B1 (en) 2002-06-13 2006-05-30 Cmi Rubber Company, Inc. High density rubber compounds
US20050079155A1 (en) 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP2319542B1 (en) 2006-02-21 2018-03-21 Nektar Therapeutics Segmented degradable polymers and conjugates made therefrom
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
AU2008331868B2 (en) * 2007-11-28 2015-02-12 Nektar Therapeutics Oligomer-tricyclic conjugates
US8829043B2 (en) 2008-02-08 2014-09-09 Nektar Therapeutics Oligome-cannabinoid conjugates
EP2265290B1 (en) * 2008-04-11 2014-06-04 Nektar Therapeutics Poly(alkylene oxide)-aryloxy-substituted propanamine conjugates
WO2009141823A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
WO2010120387A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US10220020B2 (en) * 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US9827326B2 (en) 2010-12-23 2017-11-28 Nektar Therapeutics Polymer-sunitinib conjugates
US20140331425A1 (en) 2013-05-09 2014-11-13 DeAndre Charles Baker Sqeeky kleen toilet brush

Also Published As

Publication number Publication date
EP2654797A1 (en) 2013-10-30
EP2654797B1 (en) 2017-11-08
WO2012088522A1 (en) 2012-06-28
US10220020B2 (en) 2019-03-05
US11406618B2 (en) 2022-08-09
US20140039030A1 (en) 2014-02-06
US20190142798A1 (en) 2019-05-16
JP2014501765A (ja) 2014-01-23

Similar Documents

Publication Publication Date Title
JP2014501765A (ja) ポリマー−デスエチルスニチニブコンジュゲート
JP6002149B2 (ja) ポリマー−スニチニブコンジュゲート
CA2947895C (en) Nanoparticle drug conjugates
US11007270B2 (en) Polymer-semaxanib moiety conjugates
US9095622B2 (en) Oligomer-protein tyrosine kinase inhibitor conjugates
TW201801751A (zh) 靶向構建體及其製劑
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
Kozlowski et al. Polymer-des-ethyl sunitinib conjugates
JP5792175B2 (ja) オリゴマー−カルシミメティクスコンジュゲートおよび関連化合物
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物
HK1236384A1 (en) Nanoparticle drug conjugates
HK1236384B (en) Nanoparticle drug conjugates

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160914

R150 Certificate of patent or registration of utility model

Ref document number: 6009457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250